Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680150 | 0.86 | HTR2A (0.43) | ALOX5HTR2ACYP1A2EPHX1KMT2A | |
| SCHEMBL680868 | 0.83 | ALOX5 (0.46) | ALOX5HTR2ACYP1A2PYCR1EPHX1 | |
| SCHEMBL681415 | 0.81 | CHRM2 (0.43) | ALOX5HTR2ACYP1A2PYCR1TAAR1 | |
| SCHEMBL681806 | 0.80 | CYP1A2 (0.37) | ALOX5CYP1A2SMN1; SMN2 | |
| SCHEMBL684430 | 0.79 | CYP1A2 (0.46) | ALOX5HTR2ACYP1A2EPHX1KMT2A | |
| SCHEMBL680829 | 0.79 | HTR2A (0.36) | ALOX5HTR2ACYP1A2PYCR1KMT2A | |
| SCHEMBL681418 | 0.77 | ALDH1A1 (0.36) | ALOX5CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL681240 | 0.77 | ALOX5 (0.41) | ALOX5CYP1A2EPHX1KMT2ASMN1; SMN2 | |
| SCHEMBL12188584 | 0.77 | ALOX5 (0.42) | ALOX5HTR2ACYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL2040594 | 0.75 | ESR1 (0.46) | ALOX5CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8329701-B2 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ALOX5 1635/4885HTR2A 1733/4885CYP1A2 956/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ALOX5 2032/4885HTR2A 2758/4885CYP1A2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.